The target of this SBO proposal is the establishment of a broad platform for the SialoTarg core technology and the development of a series of advanced pharmaceuticals which will enable us to tackle some of the major challenges in human and veterinary medicine. This will in turn allow the pursuit of strong and broadly enabling IPR for sialoadhesin-based macrophage targeting therapeutics.